CStone Pharmaceuticals's quarterly market cap
increased
from Dec. 2024 ($287.95 Mil) to Jun. 2025 ($705.08 Mil) and
increased
from Jun. 2025 ($705.08 Mil) to Dec. 2025 ($1,316.23 Mil).
CStone Pharmaceuticals's annual market cap
declined
from Dec. 2023 ($409.38 Mil) to Dec. 2024 ($287.95 Mil) but then
increased
from Dec. 2024 ($287.95 Mil) to Dec. 2025 ($1,316.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CStone Pharmaceuticals's Enterprise Value for Today is $812.89 Mil.
CStone Pharmaceuticals (OTCPK:CSPHF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CStone Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CStone Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where CStone Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CStone Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CStone Pharmaceuticals (CSPHF) has a Market Cap of $896.86 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CStone Pharmaceuticals and its competitors. According to the industry distribution chart, CStone Pharmaceuticals ranks #277 out of 1428 companies in the Biotechnology industry, placing it in the top 19.4%.
Is CStone Pharmaceuticals' Market Cap too high?
CStone Pharmaceuticals' current Market Cap is $896.86 Mil. The Biotechnology industry median Market Cap is 114.03. CStone Pharmaceuticals' value of $896.86 Mil is 686.5% above this industry median. Based on the distribution chart, CStone Pharmaceuticals ranks #277 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CStone Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CStone Pharmaceuticals ranks #277 out of 1428 companies for Market Cap. This places CStone Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. CStone Pharmaceuticals' value of $896.86 Mil is 686.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CStone Pharmaceuticals's current Market Cap of $896.86 Mil is 686.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CStone Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CStone Pharmaceuticals's current Market Cap is $896.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.59 — trading 296.3% above its estimated fair value. The current Market Cap is $896.86 Mil and 686.5% above the Biotechnology industry median of 114.03. CStone Pharmaceuticals' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Market Cap is $896.86 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?
Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.59 is trading 296.3% above its estimated GF Value™ of $0.15.
GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CSPHF:
Market Cap: $896.86 Mil
GF Value™: $0.15 vs. price of $0.59 (296.3% above fair value)
Industry Position: 686.5% above the Biotechnology median (#277 of 1428)
No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
38GF Score
Get the complete analysis for CSPHF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPHF has been successfully added to your 
